Please login to the form below

Not currently logged in
Email:
Password:

Stemcentrx

This page shows the latest Stemcentrx news and features for those working in and with pharma, biotech and healthcare.

Strike three for Rova-T has AbbVie cutting its losses

Strike three for Rova-T has AbbVie cutting its losses

The drugmaker acquired Rova-T via its $9.8bn takeover of  Stemcentrx three years ago, on the back of encouraging mid-stage clinical data with the drug in small cell lung ... At the time of the Stemcentrx acquisition Rova-T had been tipped as a possible

Latest news

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    Not content with the Stemcentrx acquisition, in April AbbVie also closed two other oncology deals:. ... Licensor/Acquisition target. Licensee/Acquirer. Deal type. Product technology.  Headline $m. Stemcentrx (US).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Infographics